TP53 and posterior cortical atrophy: Tumor mutational profiles, such as driver mutations in TP53 or alterations in other tumor suppressor genes, could be associated with disparate outcomes among oligo-metastatic PCa, possibly identifying in the near future patients with aggressive features who may benefit from intensified treatment (54–56).